Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Samsung Bioepis Moves Swiftly To Denosumab Phase III

SB16 Biosimilar Rival To Prolia Progresses To Phase III Trials

Dec 15 2020

• By David Wallace

Clinical Trial — Samsung Bioepis’ SB16 Denosumab Biosimilar Moves To Phase III • Source: Shutterstock

Related Content

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Dec 01 2020

Samsung Bioepis Begins Denosumab Trials

Nov 20 2020

Celltrion To Begin Denosumab Trials Within Days

Sep 04 2020

Gedeon Richter Gearing Up For Denosumab And Tocilizumab

Aug 25 2020

Samsung Bioepis First To File EU Lucentis Rival

Oct 06 2020

Henlius Kicks Off Denosumab Trial

Nov 27 2020

Related Companies

Samsung Bioepis Co., Ltd.

Additional Topics

Biosimilars Clinical Trials Strategy BioPharmaceutical

More from Biosimilars

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window